Myasthenia Gravis Foundation of America

Name

Myasthenia Gravis Foundation of America

Legal name

Myasthenia Gravis Foundation of America, Inc.

Website

https://myasthenia.org

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Patient Advocacy and Rare Disease Nonprofit Services

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000)

akta.pro primary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Rare disease advocacy
• Patient support services
• Medical research grants
• Health education resources
• Patient registry platform

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Distribution channels4 records

Marketing channels11 records

Core offering

MGFA is a national nonprofit patient advocacy organization that provides free education, support, and resources to individuals affected by myasthenia gravis. It funds MG research through grants, operates the VRMG patient registry and MyMG mobile app for symptom tracking, runs a national helpline, support groups, and food assistance programs, and partners with pharmaceutical companies to advance treatment development. All offerings are delivered free of charge to patients and caregivers, funded by donations, grants, and sponsorships.

Product overview

MGFA operates primarily as a patient advocacy organization offering a comprehensive suite of digital resources and programs for the myasthenia gravis community. The core product is the myasthenia.org website platform, which hosts the Vitaccess Real MG Registry for patient data collection, the MyMG Mobile App for symptom tracking, and extensive educational resources including the MG Lexicon, Focus on MG magazine, and video library. Supporting programs include the MGFA Helpline, support groups, the Food Support Program for patients facing food insecurity, clinical trial listings, grant funding for MG research, and signature events including the MG Walk, National Patient Conference, and International Conference. The organization positions these resources as an integrated ecosystem supporting patients from diagnosis through ongoing disease management.

Differentiator

Problem solved

Functional benefit

Products and services

• Vitaccess Real MG (VRMG) Registry An international observational patient registry developed in partnership with Vitaccess that integrates over 10 years of legacy MGFA registry data with patient-reported outcomes and clinical data from medical records to generate decision-grade real-world evidence supporting regulatory submissions, market access, and new therapy development in myasthenia gravis.
• MyMG Mobile App A mobile application for MG patients to track symptoms, medications, and appointments as part of managing their condition. Available via the myasthenia.org platform and promoted through the Living With MG section.
• MGFA Food Support Program A direct-assistance initiative addressing food insecurity among individuals with myasthenia gravis by delivering nutritious pre-prepared meals directly to eligible MG families facing financial or food access challenges, delivered in partnership with UCB and Factor Meals. Targets 250 families in 2026.
• MG Lexicon A detailed medical terminology resource developed to improve communication between MG patients and medical professionals, helping patients understand disease terminology and manage their condition more effectively.
• Focus on MG Magazine A quarterly magazine publication highlighting impactful news in the myasthenia gravis space, patient stories, and MGFA programs and activities, available by email subscription.
• MGFA Helpline A phone helpline (1-833-647-8764) staffed by trained counselors that provides resources and direct support for individuals affected by myasthenia gravis, including patients, caregivers, and family members.
• MG Support Groups A nationwide network of local support groups connecting MG patients with peers, including the MG Friends Program (one-on-one peer mentoring) and the Myasthenia Advocacy for Young Adults program, plus dedicated resources for parents and caregivers.
• MGFA Grant Funding Programs Research grant programs funding MG scientific investigation, including High Impact Pilot Projects, Transformative Research Awards, the Nancy Law Impact Award, the Jackie McSpadden Post-Doctoral Fellowship, and Clinician Scientist Development Awards, with over $1 million dedicated to research activities annually.

Quantifiable outcome

• 250 families to receive meal deliveries through MGFA Food Support Program in 2026
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• UCBcoreStrategic or Co-development Partner · 21 April 2026UCB partnered with MGFA to launch the MGFA Food Support Program, providing premade meals delivered directly to patients with myasthenia gravis living in nutrition deserts or facing food insecurity. UCB markets Rystiggo and Zilbrysq for MG patients. The program targets 250 families in 2026.
• Factor MealscoreOthers · 20 April 2026Factor Meals is the meal provider for the MGFA Food Support Program, delivering nutritious pre-prepared meals directly to eligible MG families facing food insecurity or living in nutrition deserts.
• VitaccesscoreStrategic or Co-development Partner · 12 February 2026Vitaccess entered into an exclusive partnership with MGFA to develop the Vitaccess Real MG (VRMG) Registry, creating one of the most comprehensive patient-centered evidence platforms in myasthenia gravis. The collaboration integrates MGFA's 10+ years of legacy registry data with patient-reported outcomes and clinical data to generate decision-grade evidence supporting regulatory submissions and market access.
• argenxcoreStrategic or Co-development PartnerMGFA partnered with argenx starting in 2018 to support the development of Vyvgart (efgartigimod alfa-fcab), the first and only FDA-approved neonatal Fc receptor (FcRn) blocker for adult AChR antibody-positive MG patients. MGFA provided patient insights that informed the individualized dosing design of the clinical trial. Argenx was recognized as MGFA Partner of the Year in 2022.
• National Health CouncilminorOthersMGFA works with the National Health Council, which brings together all segments of the healthcare community to provide a united voice for people with chronic diseases and disabilities.
• Community Health CharitiesminorOthersMGFA is affiliated with Community Health Charities, which delivers diverse health charity memberships to the workplace giving sector.
• American Autoimmune Related Diseases Association (AARDA)minorOthersMGFA collaborates with AARDA, dedicated to the eradication of autoimmune diseases and alleviation of suffering through education, public awareness, research, and patient services.
• National Organization for Rare Disorders (NORD)minorOthersMGFA is a member of NORD, a federation of rare disease organizations working together to help people with rare diseases through advocacy, research, and patient services.
• National Institute of Environmental Health Sciences (NIEHS)minorOthersMGFA collaborates with NIEHS, part of the NIH, which focuses on understanding how the environment influences the development and progression of human disease.
• EveryLife Foundation for Rare DiseasesminorOthersMGFA works with the EveryLife Foundation to advance rare disease advocacy and support.
• MGFA Partner of the Year Award RecipientsminorOthersMGFA has recognized pharmaceutical partners including argenx as Partner of the Year for their contributions to bringing new treatments to MG patients.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• The ALS Association: National nonprofit dedicated to a single rare neuromuscular disease (ALS), combining research funding, patient services, advocacy, and pharma partnerships. Highly comparable operating model and stakeholder mix to MGFA, just in a different rare neuromuscular indication.
• Muscular Dystrophy Association: Large patient advocacy nonprofit funding neuromuscular disease research, running patient registries, and managing multi-disease programs. Directly comparable on the research-grant + patient-services + advocacy model that MGFA uses for a single disease.
• National Multiple Sclerosis Society: Major autoimmune neuromuscular disease nonprofit with research funding, patient support programs, advocacy, and pharma partnerships. Comparable in scale, fundraising model, and the breadth of integrated services offered to a chronic autoimmune patient population.
• Lupus Foundation of America: National nonprofit focused on a single autoimmune disease (lupus), with patient education, support services, research grants, and pharmaceutical industry partnerships. Closely mirrors MGFA's single-disease advocacy + research funding structure within the autoimmune space.
• The Myositis Association: Patient advocacy organization for myositis, another rare autoimmune muscle disease. Shares the small-staff, single-disease, support-group-driven model and the same challenges of operating in a rare autoimmune niche.
• Charcot-Marie-Tooth Association: Patient advocacy nonprofit for a rare inherited neuromuscular disorder, funding research, running patient registries, and supporting affected individuals. Strongly comparable on the rare-neuromuscular + registry-driven + pharma-partnered model.
• Parent Project Muscular Dystrophy: Rare-disease nonprofit focused on Duchenne muscular dystrophy, with patient registry, research funding, and deep pharma partnerships across an active therapeutic pipeline. Comparable to MGFA in serving a single rare neuromuscular community with an evolving drug pipeline.

Broad incumbents

• National Organization for Rare Disorders (NORD): Federation of rare disease organizations (MGFA is an affiliated member). Operates across hundreds of rare conditions rather than a single disease; broader scope and policy focus make it an umbrella incumbent rather than a direct competitor for MG-specific services.
• Arthritis Foundation: Large autoimmune and musculoskeletal disease nonprofit covering many conditions. Overlaps with MGFA in autoimmune patient advocacy and research funding but addresses a much broader disease portfolio.

Others

• American Autoimmune Related Diseases Association (AARDA): Cross-disease autoimmune advocacy nonprofit that MGFA collaborates with as an affiliated partner. Comparable mission on autoimmune awareness but operates as an umbrella advocacy body rather than a single-disease service provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/mgfamerica
• YouTubeyoutube.com/channel/UCeOJeKWofRZeocwzEpoNXJw
• Facebookfacebook.com/myasthenia-gravis-foundation-of-america-inc-311199682326315
• LinkedInlinkedin.com/company/myastheniagravisfoundationofamericainc
• Instagraminstagram.com/myastheniaorg

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myasthenia Gravis Foundation of America